Last updated on April 2018

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration


Brief description of study

This is a randomized, sham controlled, masked clinical trial of 60 study participants with glaucoma. Participants with a qualifying study eye will be randomized after screening and baseline evaluations to receive the NT-501 encapsulated cell therapy (ECT) implant or a sham surgery (control arm), and no explant will be required.

An examination for safety will occur one day and one week following implant and periodically thereafter for 24 months post-implant. Based on the primary analysis of data at 6 months, patients in the control arm may be offered the NT-501 ECT implant at the 12 month time point.

Clinical Study Identifier: NCT02862938

Contact Investigators or Research Sites near you

Start Over

Mariana Nunez

Byers Eye Institute at Stanford University
Palo Alto, CA United States
  Connect »